A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

(2014) C. H. Smorenburg et al.   ANNALS OF ONCOLOGY

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014

(2014) Volker Hanf et al.   Breast Care

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group

(2013) M.E. Hamaker et al.   BREAST

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

(2011) Martin R. Stockler et al.   JOURNAL OF CLINICAL ONCOLOGY

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

(2010) Jens Huober et al.   BMC CANCER

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial

(2010) M. Kaufmann et al.   EUROPEAN JOURNAL OF CANCER

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

(2008) G. Fountzilas et al.   BREAST CANCER RESEARCH AND TREATMENT